Evidence map›Paper›PMID 39639654›Full record

ReviewActa medica academica2024

Selenium and Triple Negative Breast Cancer.

Despoina Sidira, Angeliki Siafaka, Dimosthenis Chrysikos, Georgios Papadopoulos, Epameinondas Stratopoulos, Dimitrios Filippou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta medica academica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Despoina SidiraMedical School, National and Kapodistrian University of Athens, Athens, Greece. despinasidirag@gmail.com.
Angeliki SiafakaMedical School, National and Kapodistrian University of Athens, Athens, Greece.
Dimosthenis ChrysikosDepartment of Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Georgios PapadopoulosMedical School, National and Kapodistrian University of Athens, Athens, Greece.
Epameinondas StratopoulosMedical School, National and Kapodistrian University of Athens, Athens, Greece.
Dimitrios FilippouDepartment of Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe deadliest, most dangerous subtype of breast cancer is triple-negative, which lacks treatment targets and accounts for 30% of all breast cancer-related deaths worldwide. TNBC is characterized by the expression of no estrogen, progesterone, or human epidermal growth factor 2 receptors. This suggests that new treatment modalities with fewer adverse effects are required.

objectiveThe aim of the present study was to investigate the therapeutic potential of selenium compounds as an adjuvant therapy for Triple Negative Breast Cancer (TNBC), either on their own or in conjunction with nutritional supplements and chemotherapy medications.

methodsUsing the keywords "selenium" and "triple negative breast cancer", a thorough search was conducted in the PubMed database, yielding 23 articles. The following factors were taken into consideration for inclusion: studies using TNBC cell culture lines or in vivo tumors/specimens; full-text articles from the PubMed database; studies published in the English language; experiments with statistically significant results; and selenium used alone or in combination with other antioxidants or chemotherapy. This led to the evaluation of 13 articles in this review.

resultsThe results show that selenium therapy increased the anti-cancer drug's effects and produced tumor cytotoxicity, while reducing the cellular features of the cancer (hyperproliferation, growth, and metastasis). DISCUSSION: This study evaluated the various selenium compounds tested, the cell lines and model organisms used, the assays performed, and the cellular pathways affected.

conclusionExamining the possible benefits of selenium in TNBC treatment highlights the need for more studies to confirm selenium compounds as viable co-therapeutic agents.

Indexed as

SeleniumTriple Negative Breast NeoplasmsAnimalsAntineoplastic AgentsAntioxidantsCell Line, TumorCell ProliferationDietary SupplementsFemaleHumansSelenium CompoundsAntineoplastic AgentsAntioxidantsSeleniumSelenium CompoundsAntioxidantsOncologySeleniumTriple Negative Breast Cancer

Identifiers

PMID39639654
PMCPMC11626238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.